Ovarian cancer: emerging molecular-targeted therapies

rian cancer: emerging molecular-targeted therapies Review (3002) Total Article Views Authors: Sourbier C Published Date June 2012 Volume 2012:6 Pages 147 - 154 DOI: http://dx.doi.org/10.2147/BTT.S24155 Received: 10 March 2012 Accepted: 13 April 2012 Published: 20 June 2012 Carole Sourbier Rockville, MD, USA Abstract: With about 22,000 new cases estimated in 2012 in the US and 15,500 related deaths, ovarian cancer is a heterogeneous and aggressive disease. Even though most of patients are sensitive to chemotherapy treatment following surgery, recurring disease is almost always lethal, and only about 30% of the women affected will be cured. Thanks to a better understanding of the molecular mechanisms underlying ovarian cancer malignancy, new therapeutic options with molecular-targeted agents have become available. This review discusses the rationale behind molecular-targeted therapies and examines how newly identified molecular targets may enhance personalized therapies for ovarian cancer patients.